ArriVent BioPharma, Inc. (NASDAQ:AVBP) Given Average Recommendation of "Moderate Buy" by Analysts

Key Points

• Analysts give ArriVent an average recommendation of "Moderate Buy" from 12 firms (1 sell, 1 hold, 8 buy, 2 strong buys) with an average 1‑year price target of about $41.67, and several recent upgrades/price‑target increases (e.g., B. Riley to $45, Oppenheimer to $50, Truist to strong‑buy).
• The stock opened at $31.00, trades in a one‑year range of $16.10–$32.14, has a market cap of ~$1.37 billion and a negative P/E (-7.03); ArriVent reported a quarterly EPS of -$0.78 (beating -$0.87) while analysts forecast -$3.59 EPS for the current year.
• ArriVent is a clinical‑stage biotech focused on targeted cancer therapies, notably developing Furmonertinib, a third‑generation TKI in multiple trials including a phase 3 for EGFR‑mutant non‑small cell lung cancer.

Shares of ArriVent BioPharma, Inc. (NASDAQ:AVBP - Get Free Report) have earned an average recommendation of "Moderate Buy" from the twelve ratings firms that are presently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation, eight have issued a buy recommendation and two have given a strong buy recommendation to the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $41.6667.

A number of equities analysts have weighed in on AVBP shares. Truist Financial upgraded ArriVent BioPharma to a "strong-buy" rating in a report on Wednesday, March 25th. BTIG Research started coverage on ArriVent BioPharma in a report on Thursday, March 12th. They issued a "buy" rating and a $42.00 price target for the company. B. Riley Financial upped their price target on ArriVent BioPharma from $37.00 to $45.00 and gave the stock a "buy" rating in a report on Monday, March 23rd. Citigroup upped their price target on ArriVent BioPharma from $31.00 to $33.00 and gave the stock a "buy" rating in a report on Friday, March 6th. Finally, Oppenheimer reissued an "outperform" rating and issued a $50.00 price objective (up from $44.00) on shares of ArriVent BioPharma in a research report on Friday, March 6th.

ArriVent BioPharma Stock Performance

Shares of NASDAQ:AVBP opened at $31.00 on Friday. ArriVent BioPharma has a 1 year low of $16.10 and a 1 year high of $32.14. The stock has a market capitalization of $1.37 billion, a P/E ratio of -7.03 and a beta of 0.85. The stock has a 50-day simple moving average of $24.76 and a 200-day simple moving average of $22.43.

ArriVent BioPharma (NASDAQ:AVBP - Get Free Report) last issued its earnings results on Thursday, March 5th. The company reported ($0.78) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.87) by $0.09. Analysts predict that ArriVent BioPharma will post -3.59 earnings per share for the current year.

Institutional Trading of ArriVent BioPharma

Large investors have recently modified their holdings of the business. Bessemer Group Inc. acquired a new stake in shares of ArriVent BioPharma during the third quarter valued at about $26,000. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of ArriVent BioPharma by 27.9% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,006 shares of the company's stock valued at $40,000 after acquiring an additional 438 shares in the last quarter. Russell Investments Group Ltd. boosted its stake in shares of ArriVent BioPharma by 9,747.6% during the 3rd quarter. Russell Investments Group Ltd. now owns 2,068 shares of the company's stock valued at $38,000 after buying an additional 2,047 shares during the last quarter. BNP Paribas Financial Markets boosted its stake in shares of ArriVent BioPharma by 31.0% during the 2nd quarter. BNP Paribas Financial Markets now owns 2,571 shares of the company's stock valued at $56,000 after buying an additional 609 shares during the last quarter. Finally, Group One Trading LLC purchased a new position in shares of ArriVent BioPharma during the 4th quarter valued at approximately $57,000. 9.48% of the stock is currently owned by institutional investors and hedge funds.

ArriVent BioPharma Company Profile

ArriVent BioPharma, Inc operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.